Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SUPN Supernus Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: SUPN
Price (delayed)
$33.12
Market cap
$1.85B
P/E Ratio
29.31
Dividend/share
N/A
EPS
$1.13
Enterprise value
$1.76B
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for
Highlights
The stock's price to earnings (P/E) is 76% less than its 5-year quarterly average of 121.5 and 69% less than its last 4 quarters average of 95.5
The quick ratio has soared by 52% YoY and by 6% from the previous quarter
The EPS has declined by 16% since the previous quarter
The company's net income fell by 16% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.supernus.com
Key stats
What are the main financial stats of SUPN
Market
Valuations
Earnings
Shares outstanding
55.99M
Market cap
$1.85B
Enterprise value
$1.76B
Price to earnings (P/E)
29.31
Price to book (P/B)
1.79
Price to sales (P/S)
2.77
EV/EBIT
19.23
EV/EBITDA
10.27
EV/Sales
2.64
Revenue
$668M
Gross profit
$590.64M
Operating income
$81.56M
Net income
$61.91M
EBIT
$91.8M
EBITDA
$171.84M
Free cash flow
$163.35M
Per share
Balance sheet
Liquidity
EPS
$1.13
EPS diluted
$1.11
Free cash flow per share
$2.92
Book value per share
$18.47
Revenue per share
$11.96
TBVPS
$13.03
Total assets
$1.35B
Total liabilities
$316.59M
Debt
$26.37M
Equity
$1.03B
Working capital
$405.81M
Debt to equity
0.03
Current ratio
2.44
Quick ratio
2.16
Net debt/EBITDA
-0.52
Margins
Efficiency
Dividend
EBITDA margin
25.7%
Gross margin
88.4%
Net margin
9.3%
Operating margin
12.2%
Return on assets
4.6%
Return on equity
6.1%
Return on invested capital
25.3%
Return on capital employed
8.6%
Return on sales
13.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SUPN stock price
How has the Supernus Pharmaceuticals stock price performed over time
Intraday
-0.06%
1 week
3.56%
1 month
-0.09%
1 year
16.25%
YTD
-8.41%
QTD
5.08%
Financial performance
How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$668M
Gross profit
$590.64M
Operating income
$81.56M
Net income
$61.91M
Gross margin
88.4%
Net margin
9.3%
The net margin is down by 17% since the previous quarter
The company's net income fell by 16% QoQ
The gross profit is up by 13% YoY
Supernus Pharmaceuticals's revenue has increased by 12% YoY
Price vs fundamentals
How does SUPN's price correlate with its fundamentals
Growth
What is Supernus Pharmaceuticals's growth rate over time
Valuation
What is Supernus Pharmaceuticals stock price valuation
P/E
29.31
P/B
1.79
P/S
2.77
EV/EBIT
19.23
EV/EBITDA
10.27
EV/Sales
2.64
The stock's price to earnings (P/E) is 76% less than its 5-year quarterly average of 121.5 and 69% less than its last 4 quarters average of 95.5
The EPS has declined by 16% since the previous quarter
Supernus Pharmaceuticals's equity has increased by 11% YoY
SUPN's price to book (P/B) is 6% less than its 5-year quarterly average of 1.9 but 5% more than its last 4 quarters average of 1.7
Supernus Pharmaceuticals's revenue has increased by 12% YoY
The P/S is 2.6% above the 5-year quarterly average of 2.7 and 2.6% above the last 4 quarters average of 2.7
Efficiency
How efficient is Supernus Pharmaceuticals business performance
The company's return on equity fell by 19% QoQ
The return on assets has declined by 16% since the previous quarter
SUPN's return on invested capital is down by 12% since the previous quarter
The return on sales has declined by 7% since the previous quarter
Dividends
What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SUPN.
Financial health
How did Supernus Pharmaceuticals financials performed over time
The quick ratio has soared by 52% YoY and by 6% from the previous quarter
SUPN's current ratio is up by 41% year-on-year and by 3.8% since the previous quarter
The debt is 97% smaller than the equity
Supernus Pharmaceuticals's debt to equity has decreased by 25% YoY
The debt is down by 20% year-on-year and by 3.7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.